| 000 | 01462 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513204455.0 | ||
| 264 | 0 | _c20000427 | |
| 008 | 200004s 0 0 eng d | ||
| 022 | _a0270-4137 | ||
| 024 | 7 |
_a10.1002/(sici)1097-0045(20000401)43:1<59::aid-pros8>3.0.co;2-d _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMurphy, G P | |
| 245 | 0 | 0 |
_aHigher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. _h[electronic resource] |
| 260 |
_bThe Prostate _cApr 2000 |
||
| 300 |
_a59-62 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAntigens, Surface |
| 650 | 0 | 4 |
_aCarboxypeptidases _xtherapeutic use |
| 650 | 0 | 4 |
_aDendritic Cells _xtransplantation |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aGlutamate Carboxypeptidase II |
| 650 | 0 | 4 |
_aHormones _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPeptide Fragments _xtherapeutic use |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xsecondary |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTjoa, B A | |
| 700 | 1 | _aSimmons, S J | |
| 700 | 1 | _aRogers, M K | |
| 700 | 1 | _aKenny, G M | |
| 700 | 1 | _aJarisch, J | |
| 773 | 0 |
_tThe Prostate _gvol. 43 _gno. 1 _gp. 59-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/(sici)1097-0045(20000401)43:1<59::aid-pros8>3.0.co;2-d _zAvailable from publisher's website |
| 999 |
_c10679635 _d10679635 |
||